GALT Stock Analysis: Buy, Sell, or Hold?
GALT - Galectin Therapeutics Inc.
$2.62
-0.05 (-1.87%)
▼
5d:
+9.17%
30d:
+11.49%
90d:
-17.61%
BUY
MODERATE Confidence
Analysis Updated: Jun 15, 2026 12:00 AM ET
Earnings: May 21, 2026
0d
Get Alerted When GALT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: GALT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: GALT shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: GALT is currently trading at $2.62, which is considered extended relative to its 30-day fair value range of $2.20 to $2.59.
Technical Outlook: Technically, GALT is in a strong downtrend. Immediate support is located at $2.25, while resistance sits at $2.87.
Market Sentiment: GALT has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (5th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.00 (+319.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GALT is in a strong downtrend. Immediate support is located at $2.25, while resistance sits at $2.87.
Market Sentiment: GALT has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (5th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $11.00 (+319.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.20 -
$2.59
Company Quality Score
58/100
(HOLD)
Options IV Signal
5th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 5th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 319.8% below Wall St target ($11.00)
Trading Range Analysis
30-Day Trading Range
$2.20 -
$2.59
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.50
(19.1%)
Support & Resistance Levels
Support Level
$2.26
Resistance Level
$2.87
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.94
Wall Street Target
$11.00
(+319.8%)
Share & Embed Analysis
Last updated: June 15, 2026 8:44 PM ET
Data refreshes hourly during market hours. Next update: 9:44 PM
Data refreshes hourly during market hours. Next update: 9:44 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GALT showing a specific setup today?
Insider Activity (6 Months)
2
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Kary Eldred
BUY
300 shares
2026-02-06
Jack W Callicutt
SELL
20354 shares
2026-01-06
Joel Lewis
SELL
37698 shares
2026-01-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$102 | 58 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$105 | 56 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 55 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
Advanced GALT Option Strategies
Professional options setups generated by AI based on today's GALT price and gamma walls.
